stockrowLifeward Ltd.
LFWD Healthcare Medical Devices
Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +40.8%
- Free cash flow
- −52.8%
Quarter to June 2026, against a year earlier
Follow LFWD
Alert me
Lifeward Ltd. (LFWD) EV/Sales
As of 6 November 2026, Lifeward Ltd. (LFWD) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −6.7× (March 2022) to 795× (January 2015); the current reading is higher than 42% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | 6.09% |
| FY2024 | 0.4× | (79.73%) |
| FY2023 | 2.0× | — |
| FY2022 | −3.6× | — |
| FY2021 | −4.7× | — |
| FY2020 | 0.5× | (28.17%) |
| FY2019 | 0.6× | (23.41%) |
| FY2018 | 0.8× | (72.04%) |
| FY2017 | 3.0× | (47.79%) |
| FY2016 | 5.8× | (86.30%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | 139.41% |
| Mar 2026 | 0.4× | 5.79% |
| Dec 2025 | 0.4× | (8.71%) |
| Sep 2025 | 0.5× | 182.50% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNOX Nano-X Imaging Ltd. compare | −0.5× |
| RBOT Vicarious Surgical Inc. compare | n/m |
| ARAY Accuray Incorporated compare | 0.2× |
| SNWV Sanuwave Health Inc. compare | 0.7× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| LFWD Lifeward Ltd. | 0.8× |
| PMI Flag Ship Acquisition Corp compare | 2.8× |
| ALUR Allurion Technologies, Inc. compare | 5.3× |
| HSCS HeartSciences Inc. compare | 519× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)